The Leading Community for Trusted Peptide Research & Insights
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting GHRH analog that uses a maleimidopropionic acid linker to bind serum albumin, extending its half-life to several days. This provides sustained GH elevation compared to the shorter-acting Mod GRF 1-29 (CJC-1295 without DAC).
Summary: Binds GHRH receptors on pituitary somatotrophs to stimulate sustained growth hormone release, with albumin-binding DAC technology extending half-life from minutes to days. Mechanisms (reported/proposed across domains): Growth hormone axis • Binds to GHRH receptors on anterior pituitary somatotroph cells, stimulating GH synthesis and secretion via cAMP signaling. • DAC (Drug Affinity...
Investigational - Trials Discontinued
Dose: 1–2 mg · Route: Subcutaneous (SC) · Frequency: 1–2× weekly · Duration: 8–12 weeks
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.